Anamorelin

DB06645InvestigationalSmall molecule

Investigated for use/treatment in cachexia and anorexia.

Mechanism: Pharmacologically active on Growth hormone secretagogue receptor type 1
Curator reviewed
Primary indication: Investigated for use/treatment in cachexia and anorexia.Curator reviewed
Formula / weight: C₃₁H₄₂N₆O₃ · 546.716 g/mol (avg)
Code names: ONO-7643 · RC-1291 · ST-1291

Resolves to

Compound

Structure

InChIKeyVQPFSIRUEPQQPP-MXBOTTGLSA-NSMILESCN(C)N(C)C(=O)[C@@]1(CC2=CC=CC=C2)CCCN(C1)C(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)C(C)(C)N

Targets

What you can answer from here — as of September 19, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Anamorelin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.